Picard Medical, Inc. (NYSE:PMI) shares jumped 15% to $0.31 after the bell on Tuesday after the Tucson-based medtech announced successful acute in vivo implant studies of its next-generation Emperor Total Artificial Heart (Emperor TAH) platform, conducted at the University of Arizona and Banner University Medical Center.
Next-Gen Artificial Heart Clears Animal Study
Something went wrong.
According to the company, three procedures confirmed stable hemodynamic support with no device-related intraoperative failures. The electromechanical system features an independent dual-motor ventricular design enabling side-specific control of systemic and pulmonary circulation, building on the established architecture and clinical experience of the company’s FDA- and Health Canada-approved SynCardia Total Artificial Heart.
CEO Patrick Schnegelsberg called it “another important milestone” toward a fully implantable heart.
